My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NLS Pharmaceutics Ltd. - Common Shares (NQ:NLSP)

1.780 +0.010 (+0.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NLS Pharmaceutics Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
Via ACCESSWIRE
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
Via ACCESSWIRE
Why Intelligent Bio Solutions Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares climbed 86.1% to $0.2248 after the company said it is considering strategic alternatives for its non-core operations. 
Via Benzinga
NLS Pharmaceutics Company Update and Webcast Today Postponed
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
 
Via Benzinga
Why Okta Shares Are Trading Higher By 11%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another breakdown of the biggest pre-market stock movers as we dive into all of the latest news for Thursday! 
Via InvestorPlace
NLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder Letter
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) recently released a comprehensive shareholder letter by its CEO, Alex Zwyer, detailing recent achievements and ongoing endeavors. 
Via Benzinga
NLS Pharmaceutics CEO Issues Letter to Shareholders
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers as we break down all of the biggest news on Wednesday! 
Via InvestorPlace
Why iMedia Brands Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Prestige Wealth Inc. (NASDAQ: PWM) shares jumped 65.6% to $8.28. Prestige Wealth reported pricing of $5 million initial public offering of 1 million shares of common stock at a price of $5 per... 
Via Benzinga
Why Universal Health Services Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Silicon Motion Technology Corporation (NASDAQ: SIMO) shares climbed 78.9% to $93.40 following a report suggesting China approval of the company's Maxlinear merger. 
Via Benzinga
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
Via ACCESSWIRE
NLS Pharmaceutics Releases the Results from its Annual General Meeting
Via ACCESSWIRE
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Via ACCESSWIRE
NLS Pharmaceutics Announces Company Update Webcast
Via ACCESSWIRE
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Via ACCESSWIRE
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
Via ACCESSWIRE
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
Via ACCESSWIRE
NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
Via ACCESSWIRE
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
Via ACCESSWIRE
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
Via ACCESSWIRE
Why Did Bullfrog AI Stock Jump More Than 50%?
Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University. 
Via MarketBeat
Topics Artificial Intelligence Initial Public Offering
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
Via ACCESSWIRE
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
Via ACCESSWIRE
NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
Via ACCESSWIRE
NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
Via ACCESSWIRE
NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
Via ACCESSWIRE
NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
Via ACCESSWIRE
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.